Get the Stockscreener App
1.24
12.73%
0.14
Prelude Therapeutics Inc stock is traded at $1.24, with a volume of 485.75K.
It is up +12.73% in the last 24 hours and up +45.10% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$1.10
Open:
$1.08
24h Volume:
485.75K
Relative Volume:
3.11
Market Cap:
$70.18M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.6966
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
+42.53%
1M Performance:
+45.10%
6M Performance:
+42.38%
1Y Performance:
-77.82%
1-Day Range:
$1.01
$1.25
1-Week Range:
$0.832
$1.25
52-Week Range:
$0.6101
$5.945
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.24 | 53.44M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
What makes Prelude Therapeutics Incorporated stock price move sharplyJuly 2025 Volume & Free Community Supported Trade Ideas - Newser
Price momentum metrics for Prelude Therapeutics Incorporated explainedJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser
Can swing trading help recover from Prelude Therapeutics Incorporated losses2025 Pullback Review & Pattern Based Trade Signal System - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent moveMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Is now a turning point for Prelude Therapeutics IncorporatedEarnings Recap Summary & AI Enhanced Trading Alerts - Newser
Analyzing drawdowns of Prelude Therapeutics Incorporated with statistical tools2025 Technical Overview & Growth Focused Stock Reports - Newser
Prelude Therapeutics Incorporated recovery potential after sell off2025 Breakouts & Breakdowns & Technical Confirmation Alerts - Newser
Chart overlay techniques for tracking Prelude Therapeutics IncorporatedJuly 2025 Earnings & Long Hold Capital Preservation Tips - Newser
Prelude Therapeutics (NASDAQ:PRLD) Given New $3.00 Price Target at JMP Securities - Defense World
Tick level data insight on Prelude Therapeutics Incorporated volatilityWeekly Trade Analysis & Weekly High Conviction Ideas - Newser
Prelude Therapeutics (NASDAQ:PRLD) Trading Up 8.5% – Here’s What Happened - Defense World
Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP - TipRanks
Will Prelude Therapeutics Incorporated stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
Has Prelude Therapeutics Incorporated found a price floor2025 AllTime Highs & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto Prelude Therapeutics IncorporatedTrade Exit Summary & Daily Growth Stock Tips - Newser
How to build a dashboard for Prelude Therapeutics Incorporated stockJuly 2025 Market Mood & Target Return Focused Picks - Newser
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses - MyChesCo
Best data tools to analyze Prelude Therapeutics Incorporated stockMarket Performance Summary & Advanced Technical Analysis Signals - Newser
Will Prelude Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Does Prelude Therapeutics Incorporated qualify in momentum factor screening2025 Valuation Update & Advanced Technical Analysis Signals - Newser
Is it time to cut losses on Prelude Therapeutics IncorporatedJuly 2025 Volume & AI Driven Price Forecasts - Newser
Prelude Therapeutics Incorporated stock trendline breakdown2025 Winners & Losers & Comprehensive Market Scan Insights - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionQuarterly Profit Report & Real-Time Volume Analysis Alerts - Newser
Is Prelude Therapeutics Incorporated trading at a discountTrade Risk Summary & Community Verified Trade Signals - thegnnews.com
Neurizon cites ‘strain’ at FDA as reason for delay on IND hold; Fifty Years’ $126M fund - Endpoints News
Prelude Therapeutics Reports Q2 2025 Financial Results - TipRanks
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development - TipRanks
Prelude Cuts Q2 Losses and Costs 13% - The Motley Fool
Prelude (PRLD) Announces Q2 2025 Results; Presentation Attached | PRLD SEC FilingForm 8-K - Stock Titan
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):